Contineum Therapeutics (CTNM) Q3 2026 earnings review
Contineum doubles its lung trial sites, but losses jump 46%
Contineum Therapeutics, a developer of pills for lung scarring and depression, expanded its main clinical study while losses grew. Chief executive Carmine Stengone said the company now runs over 100 trial sites across 16 countries, almost double the clinics open in June. Opening those sites pushed research spending up 45% from a year ago to $16 million, widening the net loss to $19 million.
| Cash and marketable securities | $244.5M +3% from last quarter |
|---|---|
| Research and development costs | $16.0M +45% from a year ago |
| Active lung trial sites | Over 100 up from over 55 last quarter |
| Cash runway outlook | Unchanged funded through mid-2029 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because new stock sales offset the faster cash burn, keeping the company's funding timeline intact through mid-2029. The bad news: Contineum gave no update on its depression trial with partner Johnson & Johnson, and employee costs rose even after a second-quarter research layoff.
The question now is whether Contineum can fund its lung trial through mid-2029 without continually issuing new shares. Either trial costs level off now that 100 clinics are open, or patient enrollment pushes spending higher and requires more stock sales. Fourth-quarter research expenses and share counts in the annual filing will show which path the company is on.
🐂 Bull Case
Lung Trial Sites Nearly Doubled in Three Months
Contineum is testing PIPE-791, a daily pill for idiopathic pulmonary fibrosis (IPF), a fatal disease that scars the lungs. Chief executive Carmine Stengone called the drug class an "ideal backbone for combination treatments". The biotech group wants to enroll about 324 patients in its 26-week Phase 2 study, known as PROPEL-IPF.
"We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment," Stengone said. By our math, the clinical team added at least 45 clinics and 8 countries since June. More active clinics let the trial screen patients faster across more regions.
What to watch: the date when Contineum finishes enrolling all 324 patients in the lung trial. Finishing enrollment on schedule would keep the company's one-year cash buffer after the trial intact.
Equity Sales Lifted Cash Despite Higher Spending
Pre-revenue drug developers need a large cash cushion so they can finish clinical trials without stopping research. Contineum ended September with $244.5 million in cash and marketable securities, up 34% from $182.4 million a year ago.
By our math, the balance also grew by $7.9 million from June even though the business posted an $18.7 million net loss. The company issued 1.6 million net new shares during the quarter, and additional paid-in capital rose by $25.4 million by our math. Raising money now protects the balance sheet as trial bills climb.
What to watch: cash and marketable securities at year-end alongside fourth-quarter share issuance in the annual filing. A steady cash balance without heavy new share sales would show that trial spending is leveling off.
🐻 Bear Case
Lung Trial Spending Pushed Losses Up 46%
Running a global trial in 16 countries costs much more than early lab work. For the first two quarters of 2026, Contineum spent less on research than a year earlier because older studies wound down. That pattern reversed in the third quarter as the new lung study ramped up.
- Research and development expenses: $16.0 million, up 45.4% from a year ago
- Quarterly change in research spending: up 25.9% from the second quarter by our math
- Net loss: $18.7 million, up 46.2% from $12.8 million a year ago by our math
The company attributed the jump to "higher expenses related to the PIPE-791 IPF program and employee-related costs". Because patient dosing takes 26 weeks and over 100 clinics are now active, quarterly trial bills will stay high while patients move through the study.
What to watch: fourth-quarter research and development expenses in the full-year report. Another sequential jump above 20% would test the plan to make cash last through mid-2029 without selling more stock.
Overhead Costs Rose After a Research Layoff
In the second quarter of 2026, Contineum cut discovery programs and reduced its research workforce, including its chief scientific officer, to focus on inflammatory and fibrotic drugs. A smaller research team should ease payroll pressure across the company.
Instead, general and administrative expenses rose 26.4% from a year ago to $5.0 million, and climbed 5.4% from the second quarter by our math. Contineum blamed "higher stock-based compensation and employee-related costs" for the overhead increase, and cited higher employee costs in research too. Payroll and stock awards are eating into the savings from the restructuring.
What to watch: stock-based compensation in the third-quarter filing's cash flow statement. A rising non-cash pay bill would mean shareholders face more dilution on top of the equity sales.
Partnered Depression Trial Went Quiet After Enrollment
Contineum's second clinical drug is PIPE-307, a pill that blocks the M1 receptor in the brain. Healthcare giant Johnson & Johnson licenses the drug and runs a Phase 2 trial called MOONLIGHT-1 in major depressive disorder. In the second quarter, Contineum reported that its partner finished enrolling 107 patients in June 2026.
This quarter's release gave no update on the trial's progress or when data will arrive. The risk disclaimers note that the license agreement limits Contineum's access to trial information and restricts what the biotech can disclose. Investors have no visibility into a key partnered program.
What to watch: any clinical update on PIPE-307 in the quarterly filing or from Johnson & Johnson. Continued silence into 2027 would leave the investment case resting entirely on the lung trial.
👓 Other Themes
New Shares Kept Loss Per Share Down
Contineum develops therapies "for inflammatory and fibrotic diseases with significant unmet need" and funds its work by selling stock. Weighted-average shares rose 36.5% from a year ago to 38.4 million following last year's public offering and third-quarter share issuances. Because the larger share count spread the loss across more shares, net loss per share rose 8.9% to $0.49 even though total net loss jumped 46.2%.
💲 Other KPIs
Accrued expenses — bills the company owes for services like clinical trials that it has not yet paid in cash — rose 28.5% from the second quarter by our math, reversing two quarters of declines. The balance remains 27.0% below year-end 2025. Rising accruals show that clinic billing is picking up alongside trial site openings.
Interest earned on cash and marketable securities rose 20.7% from $1.96 million a year ago, and edged up 0.9% from $2.34 million in the second quarter by our math. Higher cash balances from stock offerings generated extra yield, offsetting about 11% of the quarter's total operating expenses.
🔮 Guidance
Unchanged. Contineum still expects its $244.5 million in cash and marketable securities to fund operations through mid-2029. Stengone said this runway extends "one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial". That implies the Phase 2 lung study will finish around mid-2028. Third-quarter share sales helped keep the end date intact despite higher research spending.
❓ Key Questions
How much did third-quarter share sales raise?
Additional paid-in capital rose by $25.4 million and Class A shares rose by 2.4 million from June, but the release did not detail the at-the-market offering proceeds.
How many patients are enrolled in the lung trial?
Contineum now has over 100 active sites in 16 countries for its 324-patient study, but has not disclosed how many patients have started the 26-week dosing.
When will Johnson & Johnson report depression trial data?
Partner Johnson & Johnson finished enrolling 107 patients in the Phase 2 MOONLIGHT-1 study in June 2026, yet this release omitted any timeline for results.
What are the next steps for chronic pain?
Contineum reported Phase 1b pain data for PIPE-791 in April 2026 and still lists chronic pain as an active program, without stating if a Phase 2 trial is planned.